Cargando…

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration

BACKGROUND: Limited real‐world data exist on treatment patterns and outcomes in patients with metastatic castration‐sensitive prostate cancer (mCSPC). METHODS: A retrospective cohort study was conducted, using the Veterans Health Administration claims database (April 2013–March 2018). Among 369,734...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freedland, Stephen J., Sandin, Rickard, Sah, Janvi, Emir, Birol, Mu, Qiao, Ratiu, Anna, Hong, Agnes, Serfass, Lucile, Tagawa, Scott T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633245/ https://www.ncbi.nlm.nih.gov/pubmed/34725947 http://dx.doi.org/10.1002/cam4.4372

Ejemplares similares

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

The cost impact of disease progression to metastatic castration-sensitive prostate cancer
por: Trinh, Quoc-Dien, et al.
Publicado: (2022)

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
por: Moore, Amanda M, et al.
Publicado: (2023)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
por: Georgantopoulos, Peter, et al.
Publicado: (2019)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Re: Commentary on “The association between sexual function and prostate cancer risk in US veterans”
por: Vidal, Adriana C, et al.
Publicado: (2018)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration
por: Aspinall, Sherrie L., et al.
Publicado: (2019)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration
por: Radhakrishnan, Archana, et al.
Publicado: (2019)

A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
por: Payne, Heather, et al.
Publicado: (2021)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Prevalence of gastrointestinal disease in US Military Veterans under outpatient care at the Veterans Health Administration
por: Kent, Kelsey G
Publicado: (2021)

Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population
por: Sbarigia, Urbano, et al.
Publicado: (2020)

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration
por: Jones, Makoto M., et al.
Publicado: (2018)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

The association between sexual function and prostate cancer risk in US veterans
por: Zapata, Daniel F, et al.
Publicado: (2017)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
por: Johnston, Ashley W., et al.
Publicado: (2020)

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223
por: Al‐Ezzi, Esmail M., et al.
Publicado: (2021)

Mortality Among US Veterans Admitted to Community vs Veterans Health Administration Hospitals for COVID-19
por: Ohl, Michael E., et al.
Publicado: (2023)

Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems
por: Mannes, Zachary L., et al.
Publicado: (2022)

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data
por: Flaig, Thomas W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6e25eg7vlu3nq4t1t1nvt6hf8d